RTP Mobile Logo

A phase 3 placebo-controlled study of carboplatin/paclitaxel with or without concurrent and continuation maintenance veliparib (PARP inhibitor) in subjects with previously untreated stages III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). NCT02470585

A phase 3, randomized, double-blind, placebo-controlled, multicenter study of niraparib maintenance treatment in patients with advanced ovarian cancer following response on front-line platinum-based chemotherapy (PRIMA). NCT02655016

Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34-43. Abstract

Burger RA et al. Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG Oncology/Gynecologic Oncology Group (GOG) study. Proc ASCO 2018;Abstract 5517.

Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83. Abstract

Chan JK et al. Weekly versus every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 2016;374(8):738-48. Abstract

Clamp AR et al. Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment. Proc ESMO 2018;Abstract 943PD.

Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949-61. Abstract

du Bois A et al. Incorporation of pazopanib in maintenance therapy for ovarian cancer. J Clin Oncol 2014;32(30):3374-82. Abstract

Eskander RN et al. Correlation between surgeon’s assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2018;149(3):525-30. Abstract

Fabbro M et al. Efficacy and safety of niraparib as maintenance treatment in older patients (≥  70  years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecol Oncol 2019;152(3):560-7. Abstract

Friedlander M et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018;119(9):1075-85. Abstract

Friedlander M et al. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters — Patient-centered end points in trials of maintenance therapy. Ann Oncol 2018;29(3):737-43. Abstract

González-Martín A et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol 2019;152(1):53-60. Abstract

González-Martín A et al. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (plt) count: Blinded pooled interim safety data from the PRIMA Study. Proc ESMO 2018;Abstract 941PD.

Gopalakrishnan V et al. The influence of the gut microbiome on cancer, immunity and cancer immunotherapy. Cancer Cell 2018;33(4):570-80. Abstract

Gourley C et al. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: An extension of the ovarian BRCAness phenotype. J Clin Oncol 2010;28(15):2505-11. Abstract

Monk BJ et al. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: Blinded pooled interim safety data from the ENGOT-OV26/PRIMA study. Proc SGO 2019;Abstract 3.

Monk BJ, Chan JK. Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? Ann Oncol 2017;28(suppl 8):viii40-viii45. Abstract

Monk BJ et al. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol 2013;86(2):161-75. Abstract

Monk BJ et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2013;128(3):573-8. Abstract

Moore KN et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):636-48. Abstract

Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505. Abstract

Oza AM et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncol 2015;16(1):87-97. Abstract

Oza AM et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol 2015;16(8):928-36. Abstract

Ray-Coquard I et al. PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Proc ASCO 2017;Abstract TPS5605.

Rouzier R et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. Eur J Cancer 2017;70:133-42. Abstract

Tewari KS et al. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol 2016;27(1):114-21. Abstract

Timmermans M et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol 2018;150(3):446-50. Abstract

Trial on radical upfront surgery in advanced ovarian cancer (TRUST). NCT02828618

Walker JL et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 2019;[Epub ahead of print]. Abstract

Walker JL et al. A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): A GOG/NRG trial (GOG 252). Proc SGO 2016;Abstract 6.